PPT-IBD Management in Primary Care:

Keys to Successful Diagnosis Treatment and Ongoing Care Lisa Malter MD Professor Department of Medicine Division of Gastroenterology NYU Grossman School of Medicine New York New York Dermot McGovern MD PhD FRCP FACG. crohnsandcolitisorguk Understanding IBD Ed 5 June 2014 brPage 2br Understanding IBD About this booklet If you have recently been diagnosed with Ulcerative Colitis UC or Crohns Disease the two most common forms of In64258ammatory Bowel Disease IBD y Eva Szigethy MD, PhD . Associate Professor of Psychiatry, Pediatrics and Medicine. Director, Visceral Inflammation and Pain (VIP) Center. Division of Gastroenterology. szigethye@upmc.edu. Szigethy: Disclosures. 80% . of stores were up. . for the day. S. ales were up an average of . 70%. 98% . of stores want to do it again. 26% . of stores were up more than . 100%. People had fun!. Bookstores felt the love. Judy H. Cho, M.D. . Ward-Coleman Professor of Medicine and Genetics, Icahn School of Medicine at Mount Sinai. Central importance of human genetics. Germline. DNA variants.  disease susceptibility. Dr Hannah Gordon. Clinical Research Fellow. Chelsea and Westminster Hospital. Introduction. Review . History of twin studies. Twin studies in IBD. New molecular techniques in IBD. UK IBD Nixon Twin and Multiplex Registry. Transplant . for Refractory . Clostridium difficile. in IBD Patients. Edward V. Loftus, Jr., MD. Professor of Medicine. Division of Gastroenterology and Hepatology. Mayo Clinic. Rochester, Minnesota. Richard Driscoll. Chairman. IBD Standards Group. 2006 – 2012: IBD UK-wide projects. 2006 IBD Audit (1). 2007 IBD Standards Group formed. 2008 IBD Audit (2) into the Annual Health Check. 2009 IBD Standards launched with political lobbying. 1000 . Genomes Project Phase 3 data reveals relationships from Neandertals to present day families. Gundula Povysil. Johannes . Kepler University . Linz. Austria. Identity . by Descent (IBD). Gundula Povysil. This program will include a discussion of . investigational agents not approved by the FDA for use in the United States. . IBD Background. Evolving Treatment Landscape in IBD. Limitations of Current IBD Therapies. Jim . Gelder. , CEO, HCB. Trey Wall, VP, IBD Strategies, HCB. Garry Shelton, Director, National Sales Desk, HCB. Shift In Life Insurance Distribution. Independent . professional life agents . brokers . Management of IBD. Sprint or Marathon?. Challenges and Unmet Needs. The Sprint. When Sprinting Matters. After the Sprint. What Happens Next?. The Marathon. Long-Term Remission. Why Is It Important?. Colectomy Rates in Patients With UC Are Decreasing . Primary Care Requirements for EHR AMIA Symposium 2017 Primary Care Informatics Workgroup Alan E Zuckerman MD FAAP aez@georgetown.edu Jeffrey Weinfeld MD MBI FAAFP weinfelj@georgetown.edu Georgetown University School of Medicine colon. It is important to see a rheumatologist when this disease is suspected, as biologic treatments often help reduce complications and joint damage.DiagnosisIt is not always easy to determine if th Introduction. Canine IBD. Conclusions. References. Diagnosis. Clinical signs. Types. INTRODUCTION. The group of gastrointestinal diseases known as inflammatory bowel disease (IBD) results in the inflammation of the intestines and chronic symptoms related to gastrointestinal system..